# Population health impact > Population health impact is the measurable or projected effect of a therapy or strategy on disease burden, healthcare use, morbidity or mortality across a defined population. Source: https://www.visfo.health/glossary/population-health-impact Updated: 2026-08-16T21:55:01.198315+00:00 What is population health impact? Population health impact is the measurable or projected effect of a medical product, service or health strategy on outcomes across a defined population. It assesses changes in [disease burden](/glossary/disease-burden), healthcare utilisation, morbidity or mortality, rather than focusing only on outcomes among individual patients who receive treatment. The assessment accounts for how many eligible people are reached and what happens in routine practice. Treatment uptake, access, adherence, persistence, care pathways and health disparities can therefore materially change the impact attributed to an intervention. Why does population health impact matter in market access? Population health impact helps [market access](/glossary/market-access) teams show whether clinical benefits can translate into meaningful gains at scale. A treatment may work well for an individual patient but have limited population impact if diagnosis is low, access is restricted or few eligible patients start and remain on treatment. For payers and policymakers, the analysis can support reimbursement, service planning and public health decisions. It also strengthens the product’s real-world value narrative by connecting clinical evidence with the practical conditions required to improve outcomes across the target population. How is population health impact estimated or measured? Teams first define the population, setting, comparator and time horizon. They then estimate the difference between outcomes under current practice and outcomes under a scenario in which the product or strategy is introduced. A typical assessment covers: - The size and characteristics of the eligible population. - Baseline incidence, prevalence, outcomes and healthcare use. - Comparative treatment effectiveness and safety. - Diagnosis, eligibility, uptake, access, adherence and persistence. - Changes in events such as admissions, complications, disability or deaths. - Differences between demographic, geographic or clinical subgroups. Prospective estimates usually use a model to combine these inputs. Retrospective assessments use real-world data to examine observed changes after implementation. In both cases, teams should state assumptions clearly and distinguish association from impact that can reasonably be attributed to the intervention. What evidence is used in a population health impact assessment? Inputs may come from clinical trials, epidemiological studies, registries, claims data, electronic health records, prescribing data and patient or service-level research. Trial evidence can establish efficacy, while real-world evidence helps estimate reach, treatment patterns, adherence and outcomes in routine care. Evidence quality should be considered separately for each input. Where access, uptake or long-term outcomes are uncertain, scenario and sensitivity analyses should show how conclusions change under plausible assumptions. Subgroup analysis is important when average results could conceal unequal access or outcomes. Who is responsible for developing and using the assessment? Population health impact is usually a cross-functional activity. HEOR and epidemiology teams may develop the analytical approach; medical affairs may interpret the clinical and disease context; and market access teams may adapt the findings for payer discussions. Commercial forecasts can inform uptake assumptions, but these assumptions should remain traceable and open to challenge. A good assessment has a clearly defined population, a relevant comparator, credible evidence and transparent assumptions. Common errors include applying trial efficacy directly to the whole eligible population, overlooking constraints in the care pathway, double-counting benefits, or presenting modelled projections as observed results. How does population health impact differ from related value measures? Population health impact describes the health outcomes achieved or expected across a defined population. Disease burden describes the underlying scale and consequences of the condition before, or without, the proposed change. Cost-effectiveness compares health outcomes with costs, while budget impact estimates the financial consequences for a payer. These measures are related but not interchangeable. Population health impact can inform [health technology assessment](/glossary/health-technology-assessment-hta) and [pricing and reimbursement](/glossary/pricing-and-reimbursement), but it does not by itself establish affordability, cost-effectiveness or the appropriate price of a product.